ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Hepatitis B control in jeopardy.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper analyzes the impact of delaying the Hepatitis B vaccine beyond the first day of life following the recently updated guidelines of the United States Centers for Disease Control and Prevention (CDC) regarding universal neonatal vaccination. We discuss the potential effects that delaying the initial hepatitis B vaccine dose until 2 months will have on global health communities, the economy, well-being, and development. Despite the WHO 2030 elimination goals, shifts toward delaying the newborn "birth dose" and rising vaccine hesitancy pose a risk of a public health reversal resulting in hepatitis B (HBV) remaining a global threat. We argue that maintaining universal birth-dose recommendation should remain the most reliable strategy to mitigate systemic screening gaps and achieve the global elimination of hepatitis B, along with other forms of viral hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.